Regulatory Topics-arkiv - Biosector Ltd.

Editorial illustration showing drug discovery evolving from primitive narrow target panels, through patient risk, toward modern mass spectrometry based off-target profiling and healthier treatment outcomes.

by Stefan Sandström

Modern Off-Target Profiling: The Murderous Reality Behind Clean Safety Panels

The Easy Hurdle That Kills Programs A drug candidate can clear the standard off-target panel and […]

0

Wide illustration showing Japan as an interconnected medical device market entry ecosystem, with nodes for PMDA and MHLW regulation, hospitals, reimbursement, distributors, manufacturing, digital health, and overseas investors.

by Stefan Sandström

Japan Medical Device Market Entry Strategy

Japan is no longer a market foreign medical device companies can afford to treat as “difficult […]

0

Editorial business illustration showing a giant wasp approaching a Takeda executive in a boardroom as dominoes labeled patent cliff, revenue erosion, cost savings, and workforce reduction begin to fall.

by Stefan Sandström

Takeda is Living the Japanese Proverb: “Wasp stings a crying eye”

The High Stakes of Innovation: Balancing Takeda’s $1.26B ‘Launch Machine’ and a $2.5B Antitrust Hit as […]

0

by Stefan Sandström

Let the Old Model Die: Daiichi Sankyo Is Building an Oncology Empire

Daiichi Sankyo is no longer best understood as a successful Japanese pharma company with a strong […]

0

Editorial illustration showing complex healthcare data, regulatory, and localization inputs being streamlined through a Japan-themed gateway into clear eCOA/ePRO digital tools used by a doctor and patient.

by Stefan Sandström

Bringing eCOA and ePRO Solutions to Japan? What you Need to Get Right!

Japan is one of the world’s most demanding healthcare markets. It is also one of the […]

0

by Stefan Sandström

Infographic: Organoids and Organs-On-Chips

0

Business executive overlooking Japan’s pharmaceutical opportunity, with Mount Fuji, Tokyo skyline, Shinkansen, laboratory scientists, DNA helix, medicine vials, and an upward growth graph.

by Stefan Sandström

Catching Pharmaceutical Opportunities in Japan’s Reinvented Pharmaceutical Arena

For too long, if you ask me, the Japan pharmaceutical market opportunity has been treated as […]

0

Illustration of a company at a crossroads choosing among three market access routes into Japan: Own MAH, 3rd party DMAH, or Japanese partner as MAH, shown as three numbered roads leading toward a Tokyo cityscape.

by Stefan Sandström

MAH, DMAH, or a Japanese Partner: A Strategic Choice You Need to Make Before Entering Japan

Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the […]

0

Abstract wide illustration showing Japan drug pricing from listing to post-launch revisions, using blue shapes on a sand background with red trigger markers.

by Stefan Sandström

December 15, 2025

Japan FY2026 Drug Pricing Reform Draft: What Changes at Listing, What Tightens After Launch

On December 12, 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) tabled a draft outline […]

0

Two smiling businesswomen in an office with a view of Tokyo, collaborating on a whiteboard with flowcharts and a large corkboard filled with colorful sticky notes.

by Stefan Sandström

September 15, 2025

Japan’s Pharma Ecosystem

Cracking Japan’s Pharma Ecosystem: Field Notes from ~20 Years in the Trenches Japan rewards sequencing, proof, […]

0